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Abstract
Background: Colorectal cancers (CRCs) undergo distinct genetic and epigenetic alterations. Expression of mutL
homolog 1 (MLH1), a mismatch repair gene that corrects DNA replication errors, is lost in up to 15% of sporadic
tumours due to mutation or, more commonly, due to DNA methylation of its promoter CpG island. A single
nucleotide polymorphism (SNP) in the CpG island of MLH1 (MLH1-93G>A or rs1800734) is associated with CpG
island hypermethylation and decreased MLH1 expression in CRC tumours. Further, in peripheral blood mononuclear
cell (PBMC) DNA of both CRC cases and non-cancer controls, the variant allele of rs1800734 is associated with
hypomethylation at the MLH1 shore, a region upstream of its CpG island that is less dense in CpG sites.
Results: To determine whether this genotype-epigenotype association is present in other tissue types, including
colorectal tumours, we assessed DNA methylation in matched normal colorectal tissue, tumour, and PBMC DNA
from 349 population-based CRC cases recruited from the Ontario Familial Colorectal Cancer Registry. Using the
semi-quantitative real-time PCR-based MethyLight assay, MLH1 shore methylation was significantly higher in tumour
tissue than normal colon or PBMCs (P < 0.01). When shore methylation levels were stratified by SNP genotype,
normal colorectal DNA and PBMC DNA were significantly hypomethylated in association with variant SNP genotype
(P < 0.05). However, this association was lost in tumour DNA. Among distinct stages of CRC, metastatic stage IV CRC
tumours incurred significant hypomethylation compared to stage I–III cases, irrespective of genotype status. Shore
methylation of MLH1 was not associated with MSI status or promoter CpG island hypermethylation, regardless of
genotype. To confirm these results, bisulfite sequencing was performed in matched tumour and normal colorectal
specimens from six CRC cases, including two cases per genotype (wildtype, heterozygous, and homozygous
variant). Bisulfite sequencing results corroborated the methylation patterns found by MethyLight, with significant
hypomethylation in normal colorectal tissue of variant SNP allele carriers.
Conclusions: These results indicate that the normal tissue types tested (colorectum and PBMC) experience
dynamic genotype-associated epigenetic alterations at the MLH1 shore, whereas tumour DNA incurs aberrant
hypermethylation compared to normal DNA.
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Background
Colorectal cancer (CRC) develops as a result of the
accumulation of genetic and epigenetic alterations. Aber-
rant hypermethylation of CpG islands along with
genome-wide hypomethylation is a common signature
in CRC [1, 2]. While a number of genes have been
shown to incur methylation in CRC, one of the best
studied of these is the DNA mismatch repair (MMR)
gene mutL homolog 1 (MLH1) [3–6]. Loss of MLH1 or
other MMR genes leads to the accumulation of muta-
tions, particularly at repetitive microsatellite regions
leading to microsatellite instability (MSI) [6–8]. Ap-
proximately 15% of CRCs exhibit the MSI-high (MSI-
H) phenotype, and the majority of these cases have
deficient MMR function due to hypermethylation in-
curred at the MLH1 promoter CpG island [5, 9].
Germline mutations of MLH1 or other MMR genes,
including mutS homolog 2 (MSH2), mutS homolog 6
(MSH6), and PMS1 homolog 2, mismatch repair system
component (PMS2), lead to Lynch Syndrome accounting
for approximately 2–5% of CRCs [10, 11]. Mutations in
APC cause familial adenomatous polyposis, occurring in
<1% of CRCs [12, 13]. While these and several other
rarer germline gene mutations are known contributors to
~10% of CRCs, twin and family studies have estimated the
heritability of CRC to be up to 35% [14]. Single nucleotide
polymorphisms (SNPs) have been estimated to account
for at least 7.42% of this heritability [15].
A number of genome-wide association studies (GWAS)
have established susceptibility loci for CRC, including at
8q24, 11q23, and others [16–20]. It has previously been
demonstrated that a SNP in the promoter CpG island of
MLH1 (MLH1-93G>A, rs1800734) is associated with
MLH1 CpG island hypermethylation, loss of protein
expression, MSI, and overall increased risk of MSI-H CRC
[21, 22]. A subsequent study implicated the variant A
allele of the SNP as contributing to increased risk of CRC
overall, though another study refuted this [23, 24]. While
the overall status of this SNP as a risk factor for CRC
needs further clarification, what is clear is that it plays a
role in MSI-H CRC and MLH1 CpG island methylation
status. Interestingly, further study of SNP rs1800734 in
peripheral blood mononuclear cell (PBMC) DNA using
Illumina 450K methylation arrays indicated a different
phenomenon occurring upstream of this SNP and the
CpG island in which it is located. At the MLH1 shore in
PBMCs of both CRC cases and controls, we observed
significant hypomethylation in association with variant
SNP genotype [25].
Although the majority of DNA methylation research
has focused on CpG islands, whole-genome methylation
studies have shown that methylation changes at other
non-coding regulatory regions such as CpG shores and
enhancers may also be implicated in tumourigenesis
[26, 27]. CpG shores are regions flanking some CpG
islands that are less dense in CpG dinucleotides than
the corresponding islands are. Differential shore methy-
lation has been shown to discriminate between normal
and tumour DNA in colorectal, prostate, and breast
cancer, among other diseases [26, 28, 29].
While the mechanisms that direct DNA methylation pat-
terns are not yet completely understood, it is guided at least
in part by DNA sequence [30–33]. We have previously
demonstrated DNA variant-associated CpG shore hypome-
thylation in PBMCs while CpG island hypermethylation
was shown in CRC tumours, both of which occur in associ-
ation with the same single nucleotide change [22, 25]. In
this study, DNA methylation of the MLH1 shore was inves-
tigated in a large cohort of 349 population-based CRC cases
to determine its association with rs1800734 SNP genotype
in normal colorectal tissue, colorectal tumours, and PBMCs
of the same patients. These results indicate that static
genetic variants can dynamically modulate epigenetic regu-




Participants in this study were recruited through the
Ontario Familial Colorectal Cancer Registry (OFCCR),
which is part of the Colon Cancer Family Registry, a
consortium supported by the US National Cancer Insti-
tute. Recruitment of primary CRC cases and controls
was population-based and has been described previously
[34]. Briefly, residents from Ontario, Canada, diagnosed
with primary CRC between June 1, 1997, and June 30,
2000, between the ages of 20 and 74 were eligible for
recruitment during phase I. For phase II, individuals
with incident CRC under the age of 50 diagnosed in
Ontario between January 2003 and December 2006 were
recruited. Additional clinic-based recruitment was per-
formed to recruit individuals diagnosed with CRC above
the age of 49 with fresh frozen tumour specimens avail-
able at the biospecimen repository. Familial adenomatous
polyposis cases were excluded from both phase I and II.
Cases with non-white, mixed ethnic, or unknown back-
ground were excluded from the current study due to the
high proportion of self-reported Caucasians. Participants
provided blood, tumour, and non-neoplastic colorectal
mucosa samples, henceforth referred to as normal colo-
rectal mucosa. These blood and tissue samples were
obtained with informed written consent following proto-
cols approved by the research ethics board of Mount Sinai
Hospital and the University of Toronto.
Single nucleotide polymorphism genotyping
SNP selection and genotyping has been previously de-
scribed [22]. Briefly, PBMCs were isolated from blood
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samples of cases and controls by Ficoll-Paque gradi-
ent centrifugation following manufacturer’s protocol
(Amersham Biosciences, Baie d’Urfé, Quebec, Canada).
DNA was extracted from PBMCs by phenol-chloroform
or Qiagen DNA extraction kit (Qiagen Inc., Hilden,
Germany). The SNP rs1800734 was genotyped using a
fluorogenic 5ʹ nuclease polymerase chain reaction (PCR)
assay. It was also genotyped using Affymetrix GeneChip
Human Mapping 100K and 500K platforms through the
Assessment of Risk of Colorectal Tumours in Canada
project [35, 36]. Genotypes of the five OFCCR phase II
samples used for bisulfite sequencing were confirmed by
Sanger sequencing at The Centre for Applied Genomics
(TCAG), The Hospital for Sick Children, Toronto, Canada.
DNA from samples was amplified by PCR for the region in
theMLH1 promoter encompassing rs1800734 using primer
sequences: (forward) 5ʹ-CGCCACATACCGCTCGTAGT
A-3ʹ and (reverse) 5ʹ-TCCGTACCAGTTCTCAATCAT
CTC-3ʹ. Sequencing was performed at TCAG using an
internal primer (forward) 5ʹ-GTCATCCACATTCTGCG
GGA-3ʹ.
Microsatellite instability analysis
PCR was performed on tumour and matched normal
colorectal tissue DNA to compare MSI patterns as de-
scribed previously [35]. Briefly, paraffin-embedded colo-
rectal tumour tissue and normal colorectal tissue from
the same patients were microdissected for areas with
more than 70% cellularity in tumour and normal cell
populations. The MSI status was determined by using
the National Cancer Institute guidelines, assessing four
or more markers of ACTC, BAT-25, BAT-26, BAT-40,
BAT-34C4, D10S197, D18S55, D17S250, D5S346, and
MYC-L. MSI status was defined as MSI-high (MSI-H)
if ≥30% of markers were unstable; MSI low (MSI-L) if
1–29% of markers were unstable; and microsatellite
stable (MSS) if 0% of markers were unstable [36].
MethyLight
MethyLight was used to determine the DNA methyla-
tion status of the MLH1 shore in PBMCs, normal colo-
rectal tissue, and colorectal tumours of CRC cases. Fifty
nanograms of DNA was subject to bisulfite modification
with the EZ DNA Methylation Gold Kit according to
manufacturer’s protocol (Zymo Research Corp., Orange,
CA). Primers and probe were used to amplify a region of
the MLH1 shore, with ALU-C4 primers and probe used
as control. Probes contained a 5ʹ fluorescent reporter
dye and a 3ʹ quencher dye. Sequences for the MLH1
shore are as follows: (forward) 5ʹ-ATAGTTTTGATTAA
GATTAGAGGCG-3ʹ, (reverse) 5ʹ-CGATGTTTGAATA
ATTGGTTTAGG-3ʹ, and (probe) 5ʹ-AGGCGATTTG
AATTTTAGATTTTATTAACGGAA-3ʹ. Sequences for
ALU-C4 are as follows: (forward) 5ʹ-GGTTAGGTATA
GTGGTTTATATTTGTAATTTTAGTA-3ʹ, (reverse) 5ʹ-
ATTAACTAAACTAATCTTAAACTCCTAACCTCA-3ʹ
and (probe) 5ʹ-CCTACCTTAACCTCCC-3ʹ. Samples
were analysed in duplicate in 96-well plates on an ABI
7500 RT-PCR thermocycler. Percent methylated re-
ference (PMR) score was calculated using the following
calculation: [Gene of Interest/ALU-C4]sample/[Gene of
Interest/ALU-C4]CpGenome × 100%, where CpGenome
represents commercially available fully methylated
CpGenome Universal Methylated DNA (Millipore, Bil-
lerica, MA). The cases selected for MethyLight profiling
in this study were those from phase I OFCCR geno-
typed for SNP rs1800734 with available peripheral
blood mononuclear cell, non-neoplastic colorectal mu-
cosa, and tumour DNA. MLH1 CpG island methylation
was determined previously using MethyLight for these
cases in the same manner [22].
Bisulfite sequencing
Bisulfite sequencing was performed to analyse DNA
methylation in tumour and matched normal colorectal
mucosa from six CRC cases. Genomic DNA from
formalin-fixed paraffin-embedded (one case from phase
I OFCCR) or fresh frozen (five cases from phase II
OFCCR) tissue was used. DNA was treated with EZ
DNA Methylation Gold Kit for bisulfite conversion, as
described previously. Primers located within the MLH1
shore were designed as follows: (forward) 5ʹ-TTTGT
TTGAGAAGTGGATTGTTGTTG-3ʹ and (reverse) 5ʹ-T
TTCTTCACTTAAAACTATTAAACTCC-3ʹ. DNA was
amplified by PCR for each tumour and normal colorectal
sample. PCR product was purified using ChargeSwitch
PCR Clean-Up Kit (Invitrogen). PCR products were
cloned using the pGEM-T Easy Vector System (Pro-
mega, Madison, WI) and MAX Efficiency DH5α Compe-
tent Cells (Life Technologies, Carlsbad, CA) according
to manufacturer’s protocol. QIAprep Spin Miniprep Kit
was used according to protocol to extract plasmid DNA
(Qiagen, Hilden, Germany). Each successful clone was
sequenced by Sanger sequencing at TCAG and at least
15 clones were sequenced for each sample.
Statistical analysis
Sex, stage, and MSI status were compared between the
cases utilized for this study and the entire OFCCR
cohort by Pearson’s chi-square tests. Age was compared
between the two groups by Independent samples T tests.
MethyLight PMR values were utilized to build a multiple
linear regression model to assess the relationship
between methylation level at the MLH1 shore and tis-
sue type (PBMC, normal colorectal mucosa, tumour),
rs1800734 genotype, age, sex, stage (TNM stage I–III
compared to IV), MSI status, and MLH1 CpG island
methylation status. MethyLight PMR values among
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tissue type were compared using a linear mixed model,
controlling for random and fixed effects to account for
different DNA sources from the same individual. PMR
values between genotypes were compared using ANOVA
and independent samples T tests. Independent samples T
tests were used to compare methylation with clinicopatho-
logical variables of cases. A 6 × 4 contingency table and
Pearson’s chi-square tests were used to compare the sum
of methylated CpGs between genotypes for each sample
(total of 6 CpGs per clone with 15–27 clones per sample).
All tests were performed using IBM SPSS Statistics 21
with two-sided P < 0.05 defined as statistically significant.
Results
Assessment of clinicopathological variables and DNA
methylation
Genotype and clinicopathological variables for the 349
CRC cases used in this study are shown in Table 1. The
cases utilized for this project constitute only a subset of
the total cases recruited for the OFCCR. The 349 cases
selected had been previously profiled on the Illumina
Infinium HumanMethylation450 arrays, had known
rs1800734 genotype status, and had available DNA from
PBMC, normal colorectal mucosa, and tumour tissue.
These cases did not differ significantly from the entire
cohort of cases by age, sex, stage, or MSI status.
A multiple linear regression model was built to exam-
ine the relationships between methylation levels at the
MLH1 shore and rs1800734 genotype, age, sex, tumour
stage, MSI status, and MLH1 CpG island methylation
status (Table 2). Genotype was significantly associated
with methylation (r = −0.07, P = 0.045). Examination of
the relationships between methylation and clinicopa-
thological variables within each tissue type was also
performed. MLH1 shore methylation within PBMC
DNA was significantly associated with rs1800734 ge-
notype (r = −0.14, P = 0.02). Within normal colorectal
tissue DNA, shore methylation was associated with SNP
genotype (r = −0.15, P = 0.01), age (r = 0.19, P = 0.001),
and tumour stage (r = 0.13, P = 0.04). Tumour DNA
methylation was associated with tumour stage (r = -0.14,
P = 0.02).
The MLH1 shore is hypermethylated in tumour DNA
MethyLight was performed to measure methylation at
the MLH1 shore in DNA extracted from PBMCs,
Table 1 Distribution of clinicopathological features in primary colorectal carcinomas, including distribution among
genotypes of rs1800734
Feature All Genotypes GG GA AA
N (%) N (%) N (%) N (%)
Cases of primary colorectal carcinoma 349 211 (60.5) 119 (34.1) 19 (5.4)
Mean age (±SD) 61.9 (8.8) 62.0 (9.1) 62.0 (8.4) 60.8 (8.1)
Sex
Female 163 (46.7) 95 (45.0) 58 (48.7) 11 (57.9)
Male 186 (53.3) 116 (55.0) 61 (51.3) 8 (42.1)
TNM stage
1 22 (6.3) 15 (7.1) 6 (5.0) 1 (5.3)
2 81 (23.2) 52 (24.6) 27 (22.7) 2 (10.5)
3 208 (59.6) 125 (59.2) 70 (58.8) 13 (68.4)
4 21 (6.0) 12 (5.7) 8 (6.7) 1 (5.3)
Unavailable 17 (4.9) 7 (3.3) 8 (6.7) 2 (10.5)
MSI status
Stable/low 287 (82.2) 181 (85.8) 95 (79.8) 11 (57.9)
High 62 (17.8) 30 (14.2) 24 (20.2) 8 (42.1)
MLH1 CpG island
Unmethylated 300 (86.0) 187 (88.6) 98 (82.3) 15 (78.9)
Methylated 34 (9.7) 17 (8.1) 14 (11.8) 3 (15.8)
Unavailable 15 (4.3) 7 (3.3) 7 (5.9) 1 (5.3)
MMR germline mutation
No 341 (97.7) 209 (99.1) 114 (95.8) 18 (94.7)
Yes 8 (2.3) 2 (0.9) 5 (4.2) 1 (5.3)
Percentages may not add up to 100.0 due to rounding
SD standard deviation
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normal colorectal tissue, and colorectal tumours of 349
CRC patients. Mean methylation was compared using a
linear mixed model across the three tissue types that were
analysed (Fig. 1a). Mean PMR [standard deviation (SD)] in
PBMCs was 29.1% (4.5), compared to 30.5% (5.8) in
normal colorectal mucosa, and 33.3% (7.2) in tumour.
MLH1 shore methylation was significantly higher in
tumour than normal colorectal tissue (P = 0.04) and
PBMCs (P = 0.001). Mean methylation did not differ
significantly between normal colorectal tissue and
PBMCs (P = 0.22).
The MLH1 shore is hypomethylated in variant SNP carriers
in normal DNA
Mean methylation at the MLH1 shore was compared
between each genotype of rs1800734 in PBMCs, normal
colorectal tissue, and colorectal tumours by ANOVA
(Fig. 1b). In PBMCs, mean methylation (SD) of GG, GA,
and AA cases was 30.1% (4.8), 28.3% (3.6), and 22.6%
(3.0), respectively. This SNP-associated hypomethylation
was significant (P = 0.04). Comparing individual geno-
types, the methylation between GG and AA genotypes
as well as between GA and AA genotypes in PBMC
DNA was also significantly different (P = 0.003 and 0.02,
respectively). These findings in PBMC DNA utilizing
RT-PCR-based MethyLight technique confirmed our
previously published Illumina array-based results indi-
cating SNP-associated hypomethylation of the MLH1
shore region [25]. Comparing methylation among geno-
types in normal colorectal tissue, mean methylation (SD)
of GG, GA, and AA cases was 32.8% (6.5), 27.3% (4.5),
and 24.0% (3.2), respectively, and these results were also
significant (P = 0.005). Comparing individual genotypes,
the shore methylation between GG and GA genotypes as
well as between GG and AA genotypes was also signifi-
cantly different (P = 0.003 and 0.002, respectively). In
tumour samples stratified by genotype, mean methyla-
tion (SD) of individuals with the wildtype GG genotype
was 33.3% (7.4), while in GA individuals it was 32.8%
(7.0), and 37.0% (7.3) in AA individuals. Methylation did
not differ significantly in tumour DNA of CRC cases re-
gardless of SNP rs1800734 genotype, either by all three
genotypes or individual genotype comparisons (e.g., GG
vs. GA) (P > 0.05).
Tumour hypermethylation at the MLH1 shore is driven by
variant SNP allele
Mean methylation was compared within each genotype
of rs1800734, shown in Fig. 1c, to examine the methyla-
tion patterns across normal and tumour DNA at the
MLH1 shore. Among individuals with the wildtype GG
genotype of rs1800734, mean methylation (SD) was
30.1% (4.8) in PBMCs, 32.8% (6.5) in normal colorectal
tissue, and 33.3% (7.4) in tumour tissue, which did not
differ significantly (P = 0.15). In heterozygous individuals
carrying the GA genotype, mean methylation (SD) was
28.3% (3.6) in PBMCs, 27.3% (4.5) in normal colorectal
tissue, and 32.8% (7.0) in tumour, which differs signifi-
cantly between tissues (P = 0.008). Lastly, in homozygous
variant individuals carrying the AA genotype, mean
methylation (SD) was 22.6% (3.0) in PBMCs, 24.0% (3.2)
in normal colorectal tissue, and 37.1% (7.3) in tumour
tissue, which also varied significantly between tissues
(P = 0.01). Overall, significant hypermethylation in tu-
mours compared to normal DNA is incurred only in
individuals carrying one or two variant alleles of
rs1800734, either GA or AA.
The MLH1 shore is hypomethylated in stage IV CRC, not
associated with CpG island methylation or MSI
MLH1 shore methylation in tumours was tested for
associations with various clinicopathological variables of
the 349 CRC cases that were assessed by MethyLight.
Tumour stage and MLH1 shore methylation in tumour
DNA was compared. The mean methylation (SD) of
stage I–III tumours was 34.1% (7.3) versus 20.8% (3.6) in
stage IV cases, which was highly significantly different
(P = 6.2 × 10−5) (Fig. 2). Hypomethylation in stage IV
cases was apparent for all cases, regardless of SNP geno-
type. In GG cases mean methylation was 33.6% (7.4) for
Table 2 Multiple linear regression model for all DNA sources as well as PBMC, normal colorectal mucosa, and CRC tumour DNA
All DNA sources PBMC Normal colon Tumour
Variable r P r P r P r P
Tissue 0.06 0.07
rs1800734 −0.07 0.045 −0.14 0.02 −0.15 0.01 0.03 0.58
Age 0.07 0.05 −0.05 0.28 0.19 0.001 0.04 0.36
Sex 0.0002 0.78 0.06 0.47 0.003 0.77 −0.04 0.54
Stage −0.01 0.79 0.11 0.07 0.13 0.04 −0.14 0.02
MSI status 0.03 0.93 0.05 0.48 0.04 0.91 0.01 0.70
MLH1 CpG island methylation −0.03 0.49 −0.02 0.60 −0.02 0.57 −0.04 0.39
Significant results are italicized
The Pearson correlation (r) and P value for each variable are described
Savio et al. Clinical Epigenetics  (2017) 9:26 Page 5 of 13
Fig. 1 Mean percent methylated reference (PMR) of the MLH1 shore. MethyLight was utilized to determine PMR in PBMC, normal colorectal
tissue, and colorectal tumour DNA of 349 population-based CRC cases. All cases were genotyped for SNP rs1800734. There were 211 wildtype
(GG), 119 heterozygous (GA), and 19 homozygous variant (AA) carriers. a Mean MLH1 shore methylation in each DNA source. b Mean MLH1 shore
methylation in each DNA source stratified by genotype of rs1800734. c Mean MLH1 shore methylation for each genotype of rs1800734 stratified
by DNA source. *P < 0.05 and **P < 0.01
Savio et al. Clinical Epigenetics  (2017) 9:26 Page 6 of 13
stage I–III and 22.4% (4.3) for stage IV (P = 0.02). In GA
cases mean methylation was 33.7% (7.1) for stage I–III
and 18.4% (2.4) for stage IV (P = 0.001). There was only
one stage IV case with the AA genotype thus no P value
was calculated.
Mean methylation (SD) in tumours of cases with MSI-
H phenotype was 32.9% (5.7), which did not differ from
the 33.2% (7.5) observed in MSS/MSI-L cases (P = 0.90).
When stratified by rs1800734 SNP genotype, methyla-
tion still did not differ significantly between MSI-H and
MSS/MSI-L cases (all P > 0.05). We next tested whether
or not methylation of the MLH1 CpG island in tumour
DNA was associated with MLH1 shore methylation in
tumour DNA of the same individuals. Cases were con-
sidered methylated at the MLH1 CpG island if PMR was
greater or equal to 10%, as has been previously estab-
lished [22, 37]. Mean MLH1 shore methylation was
33.4% (7.4) in tumour DNA of cases that were unmethy-
lated at the island while methylation was 30.4% (5.9) at
the shore of cases that were methylated at the CpG
island, which did not differ significantly (P = 0.41). Since
it has previously been demonstrated that MLH1 CpG
island hypermethylation is associated with rs1800734
variant genotype, we assessed whether shore methylation
was associated with CpG island methylation stratified by
genotype; however, there were no significant associations
(all P > 0.05). Thus, regardless of genotype, MLH1 shore
methylation is not associated with CpG island methyla-
tion or MSI status.
MLH1 shore methylation level in PBMCs or normal
colorectal tissue was not significantly associated with
MSI status, tumour MLH1 CpG island hypermethyla-
tion, or tumour stage for all cases or when stratified by
SNP genotype of rs1800734 (all P > 0.05).
Bisulfite sequencing confirms SNP-associated hypomethy-
lation of MLH1 shore in normal colorectal DNA
Bisulfite sequencing was performed on a 232-base-pair
region of the MLH1 shore containing six CpGs, which
we refer to as CpG 1 to 6 in a 5 to 3 direction
(Fig. 3a). CpGs 2–5 were included in the MethyLight
primer and probe sequences. Normal colorectal DNA
and tumour DNA was analysed from six CRC cases,
comprising of two samples with each genotype (GG,
GA, and AA). For each sample, 15 to 27 clones were
sequenced, and the methylation patterns are shown in
Fig. 3b. Visual inspection of the methylation patterns
Fig. 2 Bisulfite sequencing of the MLH1 shore in normal colorectal tissue and matched colorectal tumours. a The MLH1 upstream region is
indicated, including rs1800734 coordinates. The position of each CpG interrogated by bisulfite sequencing relative to the MLH1 translation start
site is designated by a circle. Each CpG is numbered 1 to 6 in a 5ʹ to 3ʹ direction. The grey circles represent CpG sites also interrogated within the
MethyLight amplicon. b Methylation patterns in six normal colorectal tissue samples and matched tumours at the MLH1 shore, with rs1800734
genotype indicated. Empty circles represent unmethylated CpGs and filled circles represent methylated CpGs. c Graphical representation of bisulfite
sequencing results. For each sample at each CpG site, the percent of methylated CpGs was calculated. The mean percent of methylated CpGs
was then calculated for each genotype and tissue source grouping: GG normal, GA normal, AA normal, GG tumour, GA tumour, and AA tumour.
Pearson’s chi-square test was used to compare the total number of methylated CpGs at each CpG site. Error bars represent standard deviation.
**P < 0.01; ***P < 0.001
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shows hypomethylation in normal colorectal DNA in
GA and AA cases compared to GG.
The total number of methylated CpGs at each site was
compared between genotypes for normal and tumour
samples, shown in Fig. 3c. All genotypes were compared
against each other at CpGs 1 to 6 in normal colorectal
tissue. DNA methylation as assessed by bisulfite sequen-
cing was statistically significantly different among the
three genotypes. P values for each of the six CpG sites
were CpG 1 P = 2.7 × 10−4; CpG 2 P = 3.2 × 10−10; CpG 3
P = 0.001; CpG 4 P = 5.0 × 10−4; CpG 5 P = 3.5 × 10−4;
and CpG 6 P = 3.6 × 10−7. These results follow the same
significant pattern that was observed using the Methy-
Light technique (Fig. 1b); normal colorectal tissue incurs
hypomethylation at the MLH1 shore in individuals with
variant rs1800734 genotype.
The number of methylated CpGs was compared be-
tween genotypes in tumour samples. Comparing GG vs.
GA vs. AA genotypes, CpG 5 was significantly differen-
tially methylated (P = 0.002). Though CpG 5 showed
differential methylation, all other CpG site comparisons
between genotypes were not significantly statistically
different. This corresponds with the MethyLight find-
ings, in which tumour DNA methylation of the MLH1
Fig. 3 Mean percent methylated reference (PMR) of the MLH1 shore among different stages in tumour DNA. MethyLight was utilized to
determine PMR in colorectal tumour DNA of 349 population-based CRC cases. Mean MLH1 shore methylation among stage I–III and stage IV cases
is indicated. ***P < 1.0 × 10−4
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shore did not differ among genotypes of rs1800734.
Methylation was also compared between normal and
tumour DNA, and methylation at none of the six sites
was significantly different (all P > 0.05).
Discussion
Aberrant methylation changes are a hallmark of all
cancers, including CRC. Though the general pattern
observed in tumour DNA includes CpG island hyperme-
thylation with genome-wide hypomethylation, the find-
ings of the present study demonstrate that methylation
may be altered in a tissue-, locus-, and genotype-specific
manner. The critical mismatch repair gene MLH1 incurs
CpG island hypermethylation in a subset of CRC cases.
We have investigated its upstream shore and determined
that there is dynamic interplay between genotype and
epigenotype in normal and tumour DNA of CRC
patients. In normal colorectal tissue, DNA methylation
is present at the CpG shore but is hypomethylated in in-
dividuals carrying one or two variant alleles of the
rs1800734 SNP. This validates our previous array-based
results in PBMC DNA of the same CRC cases as well as
controls [25]. We also found that this SNP-associated
hypomethylation pattern is lost in tumour DNA due to
increases in CpG shore methylation in tumour com-
pared to normal colorectal DNA of SNP variant carriers.
These findings establish that the static genetic sequence
can modulate epigenetic marks in normal tissues. These
results also provide further evidence of shore methyla-
tion changes in matched tumour versus normal DNA.
This study delved into DNA methylation patterns at
the MLH1 shore, which builds upon previous studies of
MLH1 and its promoter SNP. Variant rs1800734 was
first shown to be associated with MSI-H CRCs, then
with MLH1 CpG island hypermethylation [21, 22].
Subsequent studies have also shown an association be-
tween this SNP and endometrial and lung cancer risk, as
well as worse outcome in oral squamous cell carcinoma
[38–42]. Our results have revealed the methylation pat-
terns among rs1800734 genotypes at the MLH1 shore in
PBMCs, normal colorectal tissue, and colorectal tumour
tissue. We have also previously interrogated MLH1 CpG
island methylation in PBMC, normal colorectal, and
tumour DNA [22, 25]. Figure 4 integrates methylation
data from the island and shore of MLH1 to demonstrate
the shifting epigenetic patterns at the MLH1 region.
SNP genotype is associated with the opposite direction
of methylation at the CpG shore and island in normal
and tumour DNA.
CpG shores were first described as regions up to 2
kilobases away from CpG islands that are less dense in
CpGs [26]. This original publication and subsequent
studies have demonstrated that shore methylation differs
between different tissue types [26, 43, 44]. However, in
the two ‘normal’ DNA sources assessed, non-neoplastic
colorectal mucosa and PBMCs, there were no significant
differences in MLH1 shore methylation. Having only
examined two sources of non-cancer tissues, it cannot
be said for certain what methylation patterns would be
seen in other normal tissues from these patients at this
specific region. It has also been shown that methylation
significantly differs between normal and matched
tumour DNA at CpG shore regions in multiple cancer
types [26, 28, 29, 45]. The results in this study have indi-
cated tumour hypermethylation at the MLH1 shore,
agreeing with other reports of shore hypermethylation in
cancer. Another key feature of shores is that they have
been shown to have a stronger negative correlation
between methylation and gene expression than CpG
islands [26]. However, it was also found that certain sub-
sets of genes with unmethylated islands and methylated
shores, termed ‘ravines’, in fact had high transcriptional
activity and a more transcriptionally permissive state
including higher DNase sensitivity and RNA polymerase
Fig. 4 Schematic model of DNA methylation at the MLH1 CpG island and shore. In PBMCs and normal colorectal tissue (left panel), the MLH1
shore incurs hypomethylation in association with variant SNP genotype of rs1800734. No methylation is present at the CpG island in these DNA
sources. In colorectal tumour (right panel), DNA methylation at the CpG shore loses its association with rs1800734 genotype whereas the CpG
island incurs hypermethylation in association with variant SNP genotype of rs1800734
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II binding [46]. In normal DNA and CRC tumours
without MLH1 CpG island hypermethylation, a similar
pattern is seen, with methylation at the shore and no
methylation at the CpG island. In fact, the MLH1 pro-
moter region has been well characterized, and the link
between decreased expression and hypermethylation at
specific regions in its CpG island have already been
established [47, 48]. Thus, methylation at the MLH1
shore likely does not play a large role, if any, in MLH1
expression though perhaps it functions in other ways to
create a transcriptionally permissive state as in the afore-
mentioned ‘ravines’ [46]. The exact mechanism or func-
tional role for shores remains to be elucidated.
Much research has been focused toward discerning
disease-associated SNPs. The majority of SNPs mapped
in GWAS are located in non-coding regions of the gen-
ome, thus establishing the function of SNPs has been
difficult [49–51]. Rather than altering protein function,
it has been postulated that variant SNPs cause changes
in gene expression levels [51, 52]. rs1800734 has not
clearly emerged from CRC GWAS, though a large study
has provided evidence that this SNP is a risk factor for
CRC in a study of 10,409 CRC cases and 6965 controls
with a significant per allele odds ratio of 1.06 [23].
However, meta-analyses have not supported these find-
ings [23, 24]. Regardless of its influence on overall CRC
incidence, substantial evidence exists for association of
rs1800734 with the MSI-H subtype of CRC [21, 22]. In
addition to methylation changes, we have also previously
shown functional changes incurred due to the variant
SNP genotype. Specifically, promoter constructs with
either the G or A allele were transfected into a variety of
cell lines including the CRC and normal colonic cell
lines [53]. The variant A allele exhibited significantly less
luciferase activity than the G allele in all cell lines tested.
We also established, through electrophoretic mobility
shift assay experiments in the CRC cell line HCT 116
and normal colonic cell line CCD-841-CoTr, the pres-
ence of a DNA-binding factor(s) with high affinity for
the G allele but not A [51]. This work was replicated in
HeLa cell nuclear extract by others [54]. Active promoters
bound by transcription factors and RNA polymerase II are
more resistant to incurring DNA methylation than in-
active promoters [55, 56]. Therefore, if transcription
factors are unable to bind at the A allele, this likely pro-
vides the link between variant SNP genotype and in-
creased CpG island methylation, but does not yet provide
a mechanism for methylation changes at the shore.
These results have shown an association between a
SNP and methylation at the MLH1 CpG shore in normal
colorectal tissue and PBMCs, in contrast to previous
studies, which demonstrated a SNP-methylation associ-
ation at the CpG island in tumour DNA. Tumour
methylation of the CpG island is associated with MSI-H
whereas shore methylation does not show any such
association. The reasons for this are unclear. Perhaps the
methylation changes at the CpG shore and CpG island
are two independently regulated events. Validation of
these findings in other large, well-characterized CRC
cohorts would confirm these SNP-associated methyla-
tion events. Additional studies of the MLH1 shore in
other cancer and normal tissue types would also be of
interest to determine whether this phenomenon is
restricted to colorectal tissue.
We also observed stage-specific methylation changes
at the MLH1 shore in tumour DNA. Specifically, hypo-
methylation was seen among cases with stage IV CRC,
despite the fact that across all cases tumour DNA incurs
hypermethylation of the MLH1 shore in comparison to
PBMC and normal colorectal DNA. These differences
were apparent in cases with each genotype of rs1800734.
These results further demonstrate the dynamic methyla-
tion patterns of the MLH1 shore with respect to tumour
stage, as well as SNP genotype and tissue type. Methyla-
tion studies have generally focused on hypermethylation
events in cancer; however, several have investigated
hypomethylation in advanced CRC, such as at LINE-1
repeats [55, 56]. Future validation of these findings in a
larger number of stage IV cases would be of value.
An advantage of this study is the availability of DNA
from a large population-based cohort. This cohort is
well established with DNA available from matched
blood, normal colorectal tissue, and tumour, which
enabled the ascertainment of a comprehensive view of
methylation patterns. The methylation differences mea-
sured between genotypes were significant, but relatively
subtle. For example, in normal colorectal tissue, methy-
lation was 32.8% in GG individuals, 27.3% in GA, and
24.0% in AA. Despite this, the data still demonstrated a
significant SNP association in just six samples used for
the bisulfite sequencing experiments. Across multiple
techniques in two types of normal DNA sources, whether
a large or small sample size, the genotype-epigenotype
association at the MLH1 shore is significant.
A caveat to this study is that every CpG of the MLH1
shore cannot be individually examined due to limitations
of the techniques used. MethyLight is a real-time PCR-
based method that is limited to approximately 150-base-
pair amplicons. This technique is only able to detect
methylation if all CpGs in the primer and probe
sequences are methylated, and does not account for vari-
able methylation patterns. Bisulfite sequencing will
account for variable methylation patterns that Methy-
Light cannot, and one can sequence a region up to 300
base pairs. However, this method is low throughput and
not well suited for analysis of a large number of samples.
Despite differences in technique, we were still able to
detect significant SNP-associated hypomethylation at the
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MLH1 shore in normal DNA. Another limitation is that
we only assessed methylation of the shore upstream of
the MLH1 CpG island. There is also a shore downstream
of MLH1 located within its coding region. We did not
observe SNP-associated methylation changes in our
previous methylation analysis of PBMCs in CRC cases
or controls, thus we did not pursue this downstream
shore in the current study [25].
Conclusions
These results demonstrate an association between the
promoter polymorphism rs1800734 and DNA hypome-
thylation at the MLH1 shore in normal colorectal tissue,
and also confirmed this in PBMCs, building upon our
previous work. This association is not evident in tumour
DNA from the same cases, but instead, as previously
demonstrated, this polymorphism is associated with
hypermethylation at the CpG island in MSI-H CRC. These
results reveal that the epigenetic landscape of MLH1 is
dynamically regulated at least in part by the static genetic
sequence. Additional characterization of epigenetic and/or
transcriptional regulation at the MLH1 CpG island and
shore, taking into account rs1800734 genotype differences,
may lead to further insight into mechanisms by which
polymorphisms contribute to cancer risk.
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